

Tristel plc
("Tristel" or the "Company")

Exercise of Share Options and Total Voting Rights

Tristel plc (AIM: TSTL), the manufacturer of infection prevention products, announces that it has issued and allotted a total of 10,000 new ordinary shares of 1 penny each in the capital of the Company ("Ordinary Shares") following the exercise of options by employees of the Group.

Application has been made to the London Stock Exchange for the 10,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 21 November 2024.

Total Voting Rights

After Admission, the total number of Ordinary Shares in issue will be 47,685,593 and the total number of voting rights will therefore be 47,685,593. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure Guidance and Transparency Rules.

For further information please contact:

Tristel plc
Matt Sassone, Chief Executive Officer
Liz Dixon, Chief Financial Officer

Via Walbrook PR
www.investors.tristel.com

Walbrook PR Ltd
Paul McManus
Charlotte Edgar

Tel: 020 7933 8780 or tristel@walbrookpr.com
Mob: 07980 541 893
Mob: 07884 664 686

Cavendish Capital Markets Limited
Geoff Nash / Camilla Hume / Trisya Jamaludin (Corporate Finance)
Sunila de Silva (ECM)
Louise Talbot (Sales)

Tel: 020 7220 0500

About Tristel plc

Tristel plc is a global infection prevention company focussed on the manufacture and supply of products using its unique proprietary chlorine dioxide (ClO₂) chemistry. The Company is a market leader in manual decontamination of medical devices, supplying hospitals under the [Tristel](#) brand, and under the [Cache](#) brand provides products for sporicidal surface disinfection, in a format which is a sustainable alternative to commonly used pre-wetted plastic wipes.

Tristel's head office and manufacturing facility is located in Snailwell, near Cambridge, and operates globally employing approximately 250 people across 14 subsidiaries selling into 40 countries.

The Company has been listed on the London Stock Exchange's AIM market since 2005 (AIM: TSTL).

For more information about Tristel's product range please visit: <https://tristel.com>

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact ms@seg.com or visit www.ms.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our [Privacy Policy](#).

END

IOEBMBPTMTITMAI